Highest-materiality recent filing
CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance
Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.
CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS
Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.
CONMED CFO Todd Garner to depart; transition to Special Advisor through Nov 2026
Garner's separation effective by Mar 15, 2026 or upon appointment of new CFO; he will serve as Special Advisor until Nov 2, 2026.
CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026
Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.
CONMED Q3 revenue up 6.7% to $338M; adjusted EPS $1.08; suspends dividend, authorizes $150M buyback
Diluted GAAP EPS $0.09 vs $1.57 YoY due to $19.7M product rationalization and $9.2M consulting costs.
CONMED Q2 adj EPS $1.15 beats; raises FY2025 revenue and adj EPS guidance
Q2 sales $342.3M (+3.1% YoY); GAAP EPS $0.69 (down from $0.96), adj EPS $1.15 (up from $0.98).
On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
On May 19, 2026, the Board appointed Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer of the Company effective June 1, 2026.
On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
Max materiality 0.75 · Median 0.53 · Most common event leadership